Based on this, 177Lu-CHX-A′′-DTPA-Trastuzumab has been developed, which induces dose-dependent cytotoxicity through apoptosis, providing a potential treatment for HER2-positive BC [6]. This evidence concerns the gene ERBB2 and breast cancer.